Application No. 09/857,823 Attorney Docket No. 05882.0003.PCUS00

The Response

The Examiner has required restriction to one of the following inventions:

- I. Claims 25-26, drawn to a method of treating a patient suffering from psoriasis comprising administering to the patient an antibody that binds interferon gamma.
- II. Claims 25-27 and 33-42, drawn to a method of treating a patient suffering from psoriasis comprising administering to the patient an antibody that binds interleukin 12.
- III. Claims 25-26, drawn to a method of treating a patient suffering from psoriasis comprising administering to the patient an antibody that binds an alphaR integrin subunit.
- IV. Claims 43-44, drawn to a method of treating a patient suffering from psoriasis comprising administering to the patient a pharmaceutical formulation comprising an interleukin 12 receptor or subunit thereof.

In response to the Restriction Requirement, Applicants hereby elect the invention of group II, Claims 25-27 and 33-42, drawn to a method of treating a patient suffering from psoriasis comprising administering to the patient an antibody that binds interleukin 12. Applicants expressly reserve the right to prosecute claims directed to the remaining allegedly distinct groups in one or more continuing or divisional applications

CONCLUSION

Applicants believe that the application is in good and proper condition for allowance. Early notification of allowance is earnestly solicited. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 463-8109.

Respectfully submitted,

Date: January 28, 2003

Albert P. Halluin (Reg. No. 25,227)

Viola T.Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP

301 Ravenswood Avenue, Box 34 Menlo Park, CA 94025

(650) 463-8109

Application No.: 09/857,823

Attorney Docket No.: 05882.0003.PCUS00

MARKED-UP VERSION SHOWING CHANGES MADE TO CLAIMS

25. (Twice Amended) A method of treating a patient suffering from psoriasis comprising the step of administering to the patient an antibody that binds to [an antigen selected from the group consisting of interferon gamma,] interleukin 12[, and alphaE integrin subunit].

Cancel Claims 43-44.